Stryker Corporation (NYSE: SYK - Get Free Report) has received a consensus rating of "Moderate Buy" from the nineteen ratings firms that are covering the company, Marketbeat.com reports. Six equities
Stryker Corporation (NYSE: SYK) is currently in Phase 8 of its 18-phase Adhishthana cycle on the weekly charts, and the stock has just broken its Cakra formation. This is a major bearish development w
Aging populations and wage inflation are making automation economically compelling across warehouses, factories, hospitals, and service industries. The robotics market encompasses a range of industrie
Allianz SE cut its position in shares of Stryker Corporation (NYSE: SYK) by 34.9% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Com
Advisors Capital Management LLC lifted its position in Stryker Corporation (NYSE: SYK) by 2.9% during the undefined quarter, according to the company in its most recent filing with the Securities and
Stryker (SYK) delivered strong Q3 2025 results, raising full-year guidance on robust organic growth across both MedSurg & Neurotechnology and Orthopaedics segments. SYK achieved double-digit organic s
Stryker (SYK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Stryker: Striking Again

04:30am, Monday, 03'rd Nov 2025
Stryker continues to deliver strong organic growth, having posted organic growth rates of around 10% for a long period of time now. The $4.9 billion Inari Medical acquisition announced this year will
The headline numbers for Stryker (SYK) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estim
Stryker Corporation ( SYK ) Q3 2025 Earnings Call October 30, 2025 4:30 PM EDT Company Participants Kevin Lobo - Chairman, CEO & President Jason Beach - Vice President of Finance & Investor Relations
Stryker on Thursday raised the lower end of its full-year profit forecast after beating estimates for third-quarter earnings, banking on strong demand for its medical and surgical devices.
Stryker (SYK) came out with quarterly earnings of $3.19 per share, beating the Zacks Consensus Estimate of $3.14 per share. This compares to earnings of $2.87 per share a year ago.
The medical products maker now expects sales to grow 9.8% to 10.2% in the full year.
Portage, Michigan, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the third quarter of 2025:
Beyond analysts' top-and-bottom-line estimates for Stryker (SYK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter e
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE